Data from the pivotal trial also showed the safety profile of Kisqali at the 400mg dose was well-tolerated with generally low-grade symptomatic adverse events. An updated analysis from the NATALEE ...

Data from the pivotal trial also showed that the safety profile of Kisqali at the 400mg dose was well-tolerated, with generally low-grade symptomatic adverse events. The European Commission (EC ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who ...

Immunocompromised people and those who are age 65 or older should get a second dose of the 2024-2025 COVID-19 vaccine, according to the latest recommendations from the Centers for Disease Control ...

Hydroxyzine comes as an oral tablet that’s typically taken up to four times per day. Dosage can vary depending on its use. Hydroxyzine oral tablet is a generic drug that belongs to a drug class ...

Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...

Immunocompromised adults or those who are older than 65 should get a second dose of the latest COVID-19 vaccine, the Centers for Disease Control and Prevention (CDC) officially recommended.